---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-205405"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-08-22T23:59:59+00:00"
generated_at: "2026-05-31T07:57:48.894675+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioMarin R&D chief Henry Fuchs to retire March 2025; Greg Friberg to succeed

## Summary
- Dr. Henry J. Fuchs to retire from BioMarin effective March 3, 2025.
- Dr. Greg Friberg to assume EVP, Chief Worldwide R&D Officer role on September 30, 2024.
- Fuchs will serve as senior advisor from October 1, 2024 until retirement.

## SEC filing metadata
- accession: 0001193125-24-205405
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-08-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/0001193125-24-205405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/d880241d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-205405
- JSON: https://secwatch.observer/filing/0001193125-24-205405.json
- Plain text: https://secwatch.observer/filing/0001193125-24-205405.txt

## Key facts
- Executive change
  Henry J. Fuchs retired as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.
  - Action: retired
  - Role: Executive Vice President, Chief Worldwide Research and Development Officer
  source text: On August 16, 2024, Dr. Henry J. Fuchs advised BioMarin Pharmaceutical Inc. (the “Company”) that he has elected to retire from the Company effective March 3, 2025 (the “Retirement Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/0001193125-24-205405-index.htm
- Executive change
  Greg Friberg was appointed as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: Executive Vice President, Chief Worldwide Research and Development Officer
  source text: He will continue in his current role until Dr. Greg Friberg assumes the position of Executive Vice President, Chief Worldwide Research and Development Officer, which is expected on September 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312524205405/0001193125-24-205405-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.